Stock Trading CanarySOUTH KOREA · OPENDART
Kanaph Therapeutics Inc.
카나프테라퓨틱스 · 0082N0 · KOSDAQ · Healthcare · Biotechnology
Score
48.1
Price vs insider buying
0082N0.KQ · KRW● Purchase × Sale ◇ Public disclosure ▥ 15-day cluster ·
Circles and crosses mark trade dates; diamonds below the axis mark later public disclosures. The trade became public on its disclosure date. Prices are nearest-session closes, not insider execution prices. Marker sizes are not compared when values or currencies differ.
Insider timeline
One insider bought, once (28 Oct). The share closed at 10,030.00 that day and at 9,430.00 most recently (−6.0%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
Blue line: this share's price, −67.4% over these six months
The closing price of each day, from 28,950.00 on 2026-05-11 to 9,430.00 on 2026-11-05. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
This company: insiders buying per month, last 12 months
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| Changwon Park | Executive | 1 | — | 26.7M KRW | 2026-10-28 | −6.0% |
Insiders' buying price vs the latest close
Insiders paid 8,900.00 KRW a share on average (1 purchase line, 1 buyer, 2026-10-28 – 2026-10-28). The close on 2026-11-05 was 6.0% above that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Insider trades on the exchange
Purchases and sales on the exchange in the last 12 months. The filing gives the settlement date; the trade date is two trading days earlier.
| Trade date | Filed | Insider | Role | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | 2026-11-02 | Changwon Park | Vice president | Bought on the exchange | 3,000 | ₩8,900 | ₩26.7M | DART ↗ |
Other changes in holdings · 21
Option exercises, grants, new shares, inheritance, gifts, off-exchange trades and trades by companies and funds. Not counted in the score.
| Date | Insider | Role | Reason | Shares | Filing |
|---|---|---|---|---|---|
| 2026-07-15 | Jihoon Chang | Vice president | Exercise of appraisal rights(+) | 5,000 | DART ↗ |
| 2026-07-15 | Jihoon Chang | Vice president | Exercise of appraisal rights(+) | 30,000 | DART ↗ |
| 2026-05-20 | Nahmju Kim | Managing director | Exercise of appraisal rights(+) | 4,500 | DART ↗ |
| 2026-05-20 | Donggeon Kim | Director | Exercise of appraisal rights(+) | 1,500 | DART ↗ |
| 2026-05-20 | Donggeon Kim | Director | Exercise of appraisal rights(+) | 6,000 | DART ↗ |
| 2026-05-20 | Donggeon Kim | Director | Exercise of appraisal rights(+) | 750 | DART ↗ |
| 2026-05-20 | Jihoon Chang | Vice president | Exercise of appraisal rights(+) | 25,000 | DART ↗ |
| 2026-04-17 | Donggeon Kim | Director | Exercise of appraisal rights(+) | 4,000 | DART ↗ |
| 2026-04-17 | Hayoun Jung | Managing director | Exercise of appraisal rights(+) | 1,500 | DART ↗ |
| 2026-04-17 | Hayoun Jung | Managing director | Exercise of appraisal rights(+) | 8,500 | DART ↗ |
| 2026-04-17 | Nahmju Kim | Managing director | Exercise of appraisal rights(+) | 3,500 | DART ↗ |
| 2026-04-17 | Changwon Park | Vice president | Exercise of appraisal rights(+) | 60,000 | DART ↗ |
| 2026-03-20 | Donggeon Kim | Director | Exercise of appraisal rights(+) | 7,000 | DART ↗ |
| 2026-03-20 | Donggeon Kim | Director | Exercise of appraisal rights(+) | 4,000 | DART ↗ |
| 2026-03-20 | Nahmju Kim | Managing director | Exercise of appraisal rights(+) | 2,000 | DART ↗ |
| 2026-03-20 | Jihoon Chang | Vice president | Exercise of appraisal rights(+) | 10,000 | DART ↗ |
| 2026-03-16 | GC Biopharma Corp. | 10% shareholder | New listing(+) | 1,424,333 | DART ↗ |
| 2026-03-16 | LEE BYOUNG CHUL | CEO | New listing(+) | 1,570,482 | DART ↗ |
| 2026-03-16 | Sungpil Choi | Vice president | New listing(+) | 285,000 | DART ↗ |
| 2026-03-16 | Jihoon Chang | Vice president | New listing(+) | 150,000 | DART ↗ |
| 2026-03-16 | Young Soo Yoon | Managing director | New listing(+) | 207,000 | DART ↗ |
Insiders and institutions
Insiders, ranking window: ₩26.7M net bought · buyers: 1 · last 2026-10-28
Holders of 5% and more (DART large shareholding reports)
| Holder | Of the shares | Report | As of | Change |
|---|---|---|---|---|
| LEE BYOUNG CHUL | 36.04% | general | 2026-09-18 | −2.65 pp |
| 솔리더스인베스트먼트 | 5.81% | simplified | 2026-03-23 | — |
Filings in the last 12 months
2 new · 0 raised · 1 cut · 2 fell under 5%
| As of | Holder | Report | Stake | What happened |
|---|---|---|---|---|
| 2026-09-18 | LEE BYOUNG CHUL | general | 38.69% → 36.04% | cut |
| 2026-04-23 | 프리미어파트너스 | simplified | 6.95% → 4.83% | under 5% |
| 2026-03-23 | 솔리더스인베스트먼트 | simplified | — → 5.81% | new holding |
| 2026-03-19 | 프리미어파트너스 | simplified | — → 6.95% | new holding |
| 2026-03-19 | 코오롱인베스트먼트 | simplified | — → 2.89% | under 5% |
| 2026-03-17 | LEE BYOUNG CHUL | general | — → 38.69% | holding first seen here |
Source: OpenDART, large shareholding reports (대량보유상황보고서), of the last two years; a holder that has not reported since is not shown. A holder must report on reaching 5% and on each change of 1% or more, within five working days. A general report is filed by a holder who may seek to influence the management, a simplified one by a passive investor. The percentage is the reporter's, with its related parties. Context only; not part of the score.